Introduction:
Literature review shows patient with schizophrenia have higher rates of smoking than in general population and are more refractory to smoking cessation. In addition schizophrenic patients smoke more heavily and extract more from each cigarette. Previous literature evidence have stated that effect of transdermal nicotine patches and usage of Nicotine replacement therapy in conjugation with the pharmacotherapy has a better rate of smoking cessation and reducing dependence among this population.

Objectives:
To have a better understanding on which among these would be appropriate therapeutic measures in smoking cessation and reducing nicotine dependence among this population. we systematically analyzed the available literature as it would form the highest level of evidence.

Methods:
The review included studies from 2007-2017. Only placebo controlled, Randomized control trials involving human population were considered. The titles and abstracts were independently screened by two authors and identified by the search and decided on the possible reports to be included. We obtained and examined full text reports of all potentially relevant trials, to decide whether the studies fulfilled the inclusion criteria.

Results:
Twenty relevant articles were identified (PubMed=12, Google Scholar=7, Trip database=1).Thirteen articles were eliminated after reading the title. One article was eliminated due to duplication. Six articles were selected for the abstract reading. After the abstract reading, one article was included and three were excluded. Four studies which met the inclusion criteria were taken for the present systematic review. Based on the study findings, it could be stated that the combination of Transdermal nicotine patches and sustained release of bupropion (BUP) was well tolerated, and superior to Transdermal nicotine patches and placebo for short term smoking cessation in schizophrenic patients.

Conclusion(s):
This systematic review highlights the importance of combination of transdermal nicotine patches and Bupropion in increasing smoking abstinence rates among smokers with schizophrenia.